Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has reported the grant of restricted stock units (RSUs) and stock options to newly hired non-executive employees. In July, 46,363 RSUs were granted to 16 employees. In August, 35,921 RSUs and options to purchase 18,097 shares were granted to 10 employees. The August stock options have an exercise price of $12.91 per share and a 10-year term. Both RSUs and options vest over 4 years, with 25% vesting annually. These grants were approved under Evolus' 2023 Inducement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for new employees.
Evolus, Inc. (NASDAQ: EOLS), una società di bellezza ad alte prestazioni, ha riportato l'assegnazione di unità di azioni vincolate (RSU) e opzioni su azioni ai nuovi dipendenti non esecutivi. A luglio, sono state assegnate 46.363 RSU a 16 dipendenti. A agosto, sono state assegnate 35.921 RSU e opzioni per l'acquisto di 18.097 azioni a 10 dipendenti. Le opzioni su azioni di agosto hanno un prezzo di esercizio di $12,91 per azione e un termine di 10 anni. Sia le RSU che le opzioni maturano in 4 anni, con il 25% che matura annualmente. Queste concessioni sono state approvate secondo il Piano di Incentivi per Induzione 2023 di Evolus, in conformità con la Regola di quotazione Nasdaq 5635(c)(4) come incentivo per i nuovi dipendenti.
Evolus, Inc. (NASDAQ: EOLS), una empresa de belleza de alto rendimiento, ha informado sobre la concesión de unidades de acciones restringidas (RSUs) y opciones sobre acciones a nuevos empleados no ejecutivos. En julio, se otorgaron 46,363 RSUs a 16 empleados. En agosto, se concedieron 35,921 RSUs y opciones para comprar 18,097 acciones a 10 empleados. Las opciones sobre acciones de agosto tienen un precio de ejercicio de $12.91 por acción y un término de 10 años. Tanto las RSUs como las opciones se consolidan durante 4 años, con un 25% que se consolida anualmente. Estas concesiones fueron aprobadas bajo el Plan de Incentivo por Inducción 2023 de Evolus de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivos para nuevos empleados.
Evolus, Inc. (NASDAQ: EOLS)는 성과 기반 뷰티 회사로, 새로 채용된 비임원 직원들에게 제한된 주식 단위(RSU) 및 주식 옵션을 부여했다고 보고했습니다. 7월에는 16명의 직원에게 46,363 RSU가 부여되었습니다. 8월에는 10명의 직원에게 35,921 RSU와 18,097주를 구매할 수 있는 옵션이 부여되었습니다. 8월의 주식 옵션은 주당 $12.91의 행사 가격과 10년의 기간을 가지고 있습니다. RSU와 옵션 모두 4년 동안 단계적으로 부여되며, 매년 25%가 부여됩니다. 이러한 부여는 새 직원에 대한 유인을 위한 Evolus의 2023 유인 인센티브 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)에 의해 승인되었습니다.
Evolus, Inc. (NASDAQ: EOLS), une entreprise de beauté performante, a rapporté l'octroi de unités d'actions restreintes (RSU) et d'options d'achat d'actions à des employés non exécutifs nouvellement embauchés. En juillet, 46 363 RSU ont été attribuées à 16 employés. En août, 35 921 RSU et des options d'achat de 18 097 actions ont été attribuées à 10 employés. Les options d'achat d'août ont un prix d'exercice de 12,91 $ par action et un terme de 10 ans. Tant les RSU que les options acquièrent des droits sur 4 ans, avec 25 % des droits acquis chaque année. Ces attributions ont été approuvées dans le cadre du Plan d'Incentives d'Induction 2023 d'Evolus conformément à la Règle de cotation Nasdaq 5635(c)(4) en tant qu'incitatifs pour les nouveaux employés.
Evolus, Inc. (NASDAQ: EOLS), ein Unternehmen für Performance-Beauty, hat die Gewährung von Restricted Stock Units (RSUs) und Aktienoptionen an neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Im Juli wurden 46.363 RSUs an 16 Mitarbeiter vergeben. Im August wurden 35.921 RSUs und Optionen zum Kauf von 18.097 Aktien an 10 Mitarbeiter vergeben. Die Aktienoptionen aus August haben einen Ausübungspreis von 12,91 $ pro Aktie und eine Laufzeit von 10 Jahren. Sowohl die RSUs als auch die Optionen reifen über 4 Jahre mit einer jährlichen Reifung von 25 %. Diese Zuwendungen wurden gemäß Evolus' 2023 Inducement Incentive Plan in Übereinstimmung mit der Nasdaq Listing Rule 5635(c)(4) als Anreiz für neue Mitarbeiter genehmigt.
- Evolus is expanding its workforce, potentially indicating company growth
- The company is offering competitive compensation packages to attract talent
- Issuance of new RSUs and stock options may lead to potential dilution for existing shareholders
The stock options under the August Grants have an exercise price of
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240809452447/en/
Evolus:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus
FAQ
How many RSUs did Evolus (EOLS) grant to new employees in July 2023?
What was the exercise price for the stock options granted by Evolus (EOLS) in August 2023?
What is the vesting schedule for the RSUs and stock options granted by Evolus (EOLS)?
Under which plan were these grants approved by Evolus (EOLS)?
